ID 61279
FullText URL
Author
Ichihara, Eiki Department of Allergy and Respiratory Medicine, Okayama University Hospital Kaken ID publons
Miyahara, Nobuaki Department of Medical Technology, Okayama University Graduate School of Health Sciences Kaken ID publons researchmap
Maeda, Yoshinobu Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Kaken ID researchmap
Kiura, Katsuyuki Department of Allergy and Respiratory Medicine, Okayama University Hospital ORCID Kaken ID publons researchmap
Abstract
Systemic therapy for advanced non-small cell lung cancer (NSCLC) has dramatically changed in the latest 15 years. Molecular-targeted therapy has brought about an era of precision medicine, and immune checkpoint inhibitors have brought hope for a cure for advanced NSCLC. In the wake of this remarkable advancement, lung cancer with comorbid interstitial pneumonia (IP) has been completely left behind, as most clinical trials exclude patients with comorbid IP. IP, especially idiopathic pulmonary fibrosis (IPF), is often accompanied by lung cancer, and acute exacerbation can develop during various cancer therapies, including surgery, radiotherapy and pharmacotherapy. In this review, we focus on the clinical questions concerning pharmacotherapy in cases of advanced lung cancer with comorbid IP and discuss what we can do with the currently available data.
Keywords
lung cancer
interstitial pneumonia
Published Date
2020-01-15
Publication Title
Internal Medicine
Volume
volume59
Issue
issue2
Publisher
日本内科学会
Start Page
163
End Page
167
ISSN
0918-2918
NCID
AA10827774
Content Type
Journal Article
language
英語
Copyright Holders
© 2020 by The Japanese Society of Internal Medicine
File Version
publisher
PubMed ID
NAID
DOI
Web of Science KeyUT
Related Url
isVersionOf https://doi.org/10.2169/internalmedicine.3481-19
License
https://creativecommons.org/licenses/by-nc-nd/4.0/